Scarica l'app Stockscreener
80.50
3.19%
2.49
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NUVL Giù?
Forum
Previsione
Nuvalent Inc Borsa (NUVL) Ultime notizie
Nuvalent appoints former Genentech oncology executive to board - Investing.com
Nuvalent appoints Christy Oliger to board of directors - MarketScreener
Nuvalent Adds Former Genentech Oncology SVP to Board Ahead of 2026 Launch Plans | NUVL Stock News - Stock Titan
Nuvalent’s SWOT analysis: biotech stock poised for pivotal year in NSCLC treatment - Investing.com
GAMMA Investing LLC Boosts Stake in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
(NUVL) Long Term Investment Analysis - news.stocktradersdaily.com
Rhumbline Advisers Acquires 2,572 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent’s SWOT analysis: brain-penetrant TKIs poised to reshape NSCLC stock By Investing.com - Investing.com South Africa
Nuvalent’s SWOT analysis: brain-penetrant TKIs poised to reshape NSCLC stock - Investing.com India
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results - Seeking Alpha
Nuvalent board member Emily Conley resigns By Investing.com - Investing.com Nigeria
Nuvalent board member Emily Conley resigns - Investing.com
Nuvalent Board Member Emily Conley Resigns - TipRanks
How the (NUVL) price action is used to our Advantage - news.stocktradersdaily.com
Nuvalent, Inc. Reports Q1 2025 Financial Results - TipRanks
Nuveen Asset Management LLC Has $6.62 Million Stock Position in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium - The Globe and Mail
Nuvalent (NUVL) Stock on the Rise: Decoding the 4.7% Surge and Price Potential - Daily Chhattisgarh News
Nuvalent’s SWOT analysis: cancer drug developer’s stock faces pivotal year By Investing.com - Investing.com Nigeria
Nuvalent’s SWOT analysis: cancer drug developer’s stock faces pivotal year - Investing.com Australia
Deutsche Bank AG Has $2.79 Million Stock Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Shares Acquired by Bank of America Corp DE - Defense World
BNP Paribas Financial Markets Acquires Shares of 17,366 Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Shares Sold by Dimensional Fund Advisors LP - Defense World
A Bullish 2025 Outlook For Nuvalent Inc (NASDAQ: NUVL) Shares - Stocksregister
Decoding Nuvalent Inc (NUVL): A Strategic SWOT Insight - GuruFocus
Nuvalent (NUVL) Targets Key Milestones with Solid Financial Backing | NUVL Stock News - GuruFocus
Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results - Quantisnow
Financial Health Check: Examining Nuvalent Inc (NUVL)’s Key Ratios - DWinneX
Nuvalent, Inc. (NASDAQ:NUVL) Stock Holdings Lowered by Envestnet Asset Management Inc. - Defense World
When the Price of (NUVL) Talks, People Listen - news.stocktradersdaily.com
Nuvalent Inc (NUVL) looking to reclaim success with recent performance - Sete News
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results - Seeking Alpha
Nuvalent reveals preclinical data on cancer drug zidesamtinib - Investing.com
Nuvalent Announces Publication in Molecular Cancer Therapeutics - GuruFocus
Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor - PR Newswire
Indo-Asian News Service - Indo-Asian News Service (IANS)
Nuvalent, Inc. (NASDAQ:NUVL) Position Boosted by Wells Fargo & Company MN - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Nuvalent, Inc. (NUVL): Among Takeover Rumors Hedge Funds Are Buying - Yahoo Finance
Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting - ADVFN
Is Nuvalent, Inc. (NUVL) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey
Nuvalent describes new ROS and ALK tyrosine kinase receptor inhibitors - BioWorld MedTech
UBS gives a Buy recommendation for Nuvalent Inc (NUVL) - knoxdaily.com
JPMorgan Chase & Co. Acquires 47,818 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Trend Tracker for (NUVL) - news.stocktradersdaily.com
Nuvalent Board Member Resigns, Joins Advisory Board - TipRanks
Alliancebernstein L.P. Purchases 500 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Commonwealth Equity Services LLC Raises Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Sei Investments Co. Reduces Stock Position in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent (NUVL) Gets a Buy from Barclays - The Globe and Mail
Nuvalent: Cannot Make Sense Of The Valuation - Seeking Alpha
Nuvalent stock touches 52-week low at $61.75 amid market shifts By Investing.com - Investing.com South Africa
Nuvalent stock touches 52-week low at $61.75 amid market shifts - Investing.com Australia
Norges Bank Invests $24.95 Million in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):